After the supportive Q2 figures from GSK on Wednesday, the Pacira Q2 2015 EXPAREL® sales figure yesterday was slightly weaker than expected, leading us to prudently reduce our EXPAREL® forecasts whilst remaining bullish on its long term growth potential. For example, Pacira is working on additional Phase III trials for the nerve block indication and is moving forward with a Phase III trial for oral surgery. It is also encouraging to note that Pacira has commenced discussions with partners for EX ....
31 Jul 2015
EXPAREL® Q2 sales
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
EXPAREL® Q2 sales
SkyePharma (SKP:LON) | 0 0 0.0% | Mkt Cap: 470.3m
- Published:
31 Jul 2015 -
Author:
Sheena Berry -
Pages:
3
After the supportive Q2 figures from GSK on Wednesday, the Pacira Q2 2015 EXPAREL® sales figure yesterday was slightly weaker than expected, leading us to prudently reduce our EXPAREL® forecasts whilst remaining bullish on its long term growth potential. For example, Pacira is working on additional Phase III trials for the nerve block indication and is moving forward with a Phase III trial for oral surgery. It is also encouraging to note that Pacira has commenced discussions with partners for EX ....